<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/1C4A24DC-2FF4-47B7-B5FA-46BFF24DF5AB"><gtr:id>1C4A24DC-2FF4-47B7-B5FA-46BFF24DF5AB</gtr:id><gtr:name>National Institute for Medical Research</gtr:name><gtr:address><gtr:line1>Ocean Road</gtr:line1><gtr:line2>PO Box 9653</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/F11E21C9-E05F-4173-939C-61F868FE1FBA"><gtr:id>F11E21C9-E05F-4173-939C-61F868FE1FBA</gtr:id><gtr:name>The Wellcome Trust Ltd</gtr:name><gtr:address><gtr:line1>215 Euston Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>NW1 2BE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/847CFDD6-585B-4103-BE2A-D48D56F5A7C8"><gtr:id>847CFDD6-585B-4103-BE2A-D48D56F5A7C8</gtr:id><gtr:name>University of Ghana</gtr:name><gtr:address><gtr:line1>Box LG 74</gtr:line1><gtr:line2>Legon</gtr:line2><gtr:line4>Accra</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Ghana</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5664D2BC-E7F9-4063-9DCF-2992AE5F8387"><gtr:id>5664D2BC-E7F9-4063-9DCF-2992AE5F8387</gtr:id><gtr:name>University of Yaound?</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/DE956CB8-1DF4-49EB-BC34-78BD6095649A"><gtr:id>DE956CB8-1DF4-49EB-BC34-78BD6095649A</gtr:id><gtr:name>University of KwaZulu-Natal</gtr:name><gtr:address><gtr:line1>Govan Mbeki Centre</gtr:line1><gtr:line2>Westville Campus</gtr:line2><gtr:line3>Private Bag X54001</gtr:line3><gtr:postCode>4000</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/0D763E2F-2905-41F5-8B10-AFCF8B6DA137"><gtr:id>0D763E2F-2905-41F5-8B10-AFCF8B6DA137</gtr:id><gtr:name>University of Conakry</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/EA92762E-9D7C-4DC0-A1D1-2AA2FAC579D8"><gtr:id>EA92762E-9D7C-4DC0-A1D1-2AA2FAC579D8</gtr:id><gtr:name>University of Nigeria</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/2C711771-B8F6-4CDF-9AC3-9FAB317463D9"><gtr:id>2C711771-B8F6-4CDF-9AC3-9FAB317463D9</gtr:id><gtr:name>University of Cape Town</gtr:name><gtr:address><gtr:line1>Private Bag</gtr:line1><gtr:line2>Rondebosch</gtr:line2><gtr:postCode>7700</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5C5043CE-84CE-47DF-A2F9-2C42D2F56651"><gtr:id>5C5043CE-84CE-47DF-A2F9-2C42D2F56651</gtr:id><gtr:name>University of Ibadan</gtr:name><gtr:address><gtr:line1>Ibadan</gtr:line1><gtr:line4>Oyo State</gtr:line4><gtr:line5>Nigeria</gtr:line5><gtr:postCode>900001</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Nigeria</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/B6961CB7-C2D1-4D66-A8E4-43C981AD3CF9"><gtr:id>B6961CB7-C2D1-4D66-A8E4-43C981AD3CF9</gtr:id><gtr:name>Moi University</gtr:name><gtr:address><gtr:line1>P.O. Box 1125</gtr:line1><gtr:line2>30100</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A2EC0DF1-142D-422A-AB83-724ABEC8BE19"><gtr:id>A2EC0DF1-142D-422A-AB83-724ABEC8BE19</gtr:id><gtr:name>University of the Witwatersrand</gtr:name><gtr:address><gtr:line1>University of the Witwatersrand</gtr:line1><gtr:line2>WITS</gtr:line2><gtr:line3>2050</gtr:line3><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/1FE9B7FF-1274-4320-ADE0-4E18B9D24C59"><gtr:id>1FE9B7FF-1274-4320-ADE0-4E18B9D24C59</gtr:id><gtr:name>Makerere University College of Health Sciences</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/ACCAA472-353D-4CD6-814A-04677AE5E921"><gtr:id>ACCAA472-353D-4CD6-814A-04677AE5E921</gtr:id><gtr:name>MRC/UVRI Uganda Research Unit on AIDS</gtr:name><gtr:address><gtr:line1>Uganda Virus Research Institute</gtr:line1><gtr:line2>51-59 Nakiwogo Road, PO box 49</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Uganda</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3F3999EF-63D0-468D-964D-E5D6487C764E"><gtr:id>3F3999EF-63D0-468D-964D-E5D6487C764E</gtr:id><gtr:name>University of The Gambia</gtr:name><gtr:address><gtr:line1>Chancery Building</gtr:line1><gtr:line2>Brikama Campus</gtr:line2><gtr:postCode>PO Box 353</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4E55B119-02E7-43F3-9B39-DD48A6511372"><gtr:id>4E55B119-02E7-43F3-9B39-DD48A6511372</gtr:id><gtr:name>Addenbrooke's Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A487A0BA-87A9-41A4-90BB-BF732B34EC39"><gtr:id>A487A0BA-87A9-41A4-90BB-BF732B34EC39</gtr:id><gtr:name>Howard University</gtr:name><gtr:address><gtr:line1>Howard University</gtr:line1><gtr:line2>2400 Sixth Street</gtr:line2><gtr:postCode>DC 20059</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Research Services Division</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/1C4A24DC-2FF4-47B7-B5FA-46BFF24DF5AB"><gtr:id>1C4A24DC-2FF4-47B7-B5FA-46BFF24DF5AB</gtr:id><gtr:name>National Institute for Medical Research</gtr:name><gtr:address><gtr:line1>Ocean Road</gtr:line1><gtr:line2>PO Box 9653</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/F11E21C9-E05F-4173-939C-61F868FE1FBA"><gtr:id>F11E21C9-E05F-4173-939C-61F868FE1FBA</gtr:id><gtr:name>The Wellcome Trust Ltd</gtr:name><gtr:address><gtr:line1>215 Euston Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>NW1 2BE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/847CFDD6-585B-4103-BE2A-D48D56F5A7C8"><gtr:id>847CFDD6-585B-4103-BE2A-D48D56F5A7C8</gtr:id><gtr:name>University of Ghana</gtr:name><gtr:address><gtr:line1>Box LG 74</gtr:line1><gtr:line2>Legon</gtr:line2><gtr:line4>Accra</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Ghana</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5664D2BC-E7F9-4063-9DCF-2992AE5F8387"><gtr:id>5664D2BC-E7F9-4063-9DCF-2992AE5F8387</gtr:id><gtr:name>University of Yaound?</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/DE956CB8-1DF4-49EB-BC34-78BD6095649A"><gtr:id>DE956CB8-1DF4-49EB-BC34-78BD6095649A</gtr:id><gtr:name>University of KwaZulu-Natal</gtr:name><gtr:address><gtr:line1>Govan Mbeki Centre</gtr:line1><gtr:line2>Westville Campus</gtr:line2><gtr:line3>Private Bag X54001</gtr:line3><gtr:postCode>4000</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/0D763E2F-2905-41F5-8B10-AFCF8B6DA137"><gtr:id>0D763E2F-2905-41F5-8B10-AFCF8B6DA137</gtr:id><gtr:name>University of Conakry</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/EA92762E-9D7C-4DC0-A1D1-2AA2FAC579D8"><gtr:id>EA92762E-9D7C-4DC0-A1D1-2AA2FAC579D8</gtr:id><gtr:name>University of Nigeria</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2C711771-B8F6-4CDF-9AC3-9FAB317463D9"><gtr:id>2C711771-B8F6-4CDF-9AC3-9FAB317463D9</gtr:id><gtr:name>University of Cape Town</gtr:name><gtr:address><gtr:line1>Private Bag</gtr:line1><gtr:line2>Rondebosch</gtr:line2><gtr:postCode>7700</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5C5043CE-84CE-47DF-A2F9-2C42D2F56651"><gtr:id>5C5043CE-84CE-47DF-A2F9-2C42D2F56651</gtr:id><gtr:name>University of Ibadan</gtr:name><gtr:address><gtr:line1>Ibadan</gtr:line1><gtr:line4>Oyo State</gtr:line4><gtr:line5>Nigeria</gtr:line5><gtr:postCode>900001</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Nigeria</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/B6961CB7-C2D1-4D66-A8E4-43C981AD3CF9"><gtr:id>B6961CB7-C2D1-4D66-A8E4-43C981AD3CF9</gtr:id><gtr:name>Moi University</gtr:name><gtr:address><gtr:line1>P.O. Box 1125</gtr:line1><gtr:line2>30100</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A2EC0DF1-142D-422A-AB83-724ABEC8BE19"><gtr:id>A2EC0DF1-142D-422A-AB83-724ABEC8BE19</gtr:id><gtr:name>University of the Witwatersrand</gtr:name><gtr:address><gtr:line1>University of the Witwatersrand</gtr:line1><gtr:line2>WITS</gtr:line2><gtr:line3>2050</gtr:line3><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/1FE9B7FF-1274-4320-ADE0-4E18B9D24C59"><gtr:id>1FE9B7FF-1274-4320-ADE0-4E18B9D24C59</gtr:id><gtr:name>Makerere University College of Health Sciences</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/ACCAA472-353D-4CD6-814A-04677AE5E921"><gtr:id>ACCAA472-353D-4CD6-814A-04677AE5E921</gtr:id><gtr:name>MRC/UVRI Uganda Research Unit on AIDS</gtr:name><gtr:address><gtr:line1>Uganda Virus Research Institute</gtr:line1><gtr:line2>51-59 Nakiwogo Road, PO box 49</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Uganda</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3F3999EF-63D0-468D-964D-E5D6487C764E"><gtr:id>3F3999EF-63D0-468D-964D-E5D6487C764E</gtr:id><gtr:name>University of The Gambia</gtr:name><gtr:address><gtr:line1>Chancery Building</gtr:line1><gtr:line2>Brikama Campus</gtr:line2><gtr:postCode>PO Box 353</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4E55B119-02E7-43F3-9B39-DD48A6511372"><gtr:id>4E55B119-02E7-43F3-9B39-DD48A6511372</gtr:id><gtr:name>Addenbrooke's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A487A0BA-87A9-41A4-90BB-BF732B34EC39"><gtr:id>A487A0BA-87A9-41A4-90BB-BF732B34EC39</gtr:id><gtr:name>Howard University</gtr:name><gtr:address><gtr:line1>Howard University</gtr:line1><gtr:line2>2400 Sixth Street</gtr:line2><gtr:postCode>DC 20059</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/7784DA24-BCE2-4257-9BA0-6C10D8080A03"><gtr:id>7784DA24-BCE2-4257-9BA0-6C10D8080A03</gtr:id><gtr:firstName>Jaspal</gtr:firstName><gtr:otherNames>S</gtr:otherNames><gtr:surname>Kooner</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/864BFBA7-D79D-47E2-B075-47D1F42F04CA"><gtr:id>864BFBA7-D79D-47E2-B075-47D1F42F04CA</gtr:id><gtr:firstName>Manjinder</gtr:firstName><gtr:surname>Sandhu</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/5DABC140-76D1-49D2-BDB6-0366C03E390E"><gtr:id>5DABC140-76D1-49D2-BDB6-0366C03E390E</gtr:id><gtr:firstName>Aroon</gtr:firstName><gtr:otherNames>Dinesh</gtr:otherNames><gtr:surname>Hingorani</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/161DE809-8AE4-4978-9F68-F106C8C63ED0"><gtr:id>161DE809-8AE4-4978-9F68-F106C8C63ED0</gtr:id><gtr:firstName>Nicholas</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Wareham</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/4B98F259-77FE-4FC0-9296-140C9C066977"><gtr:id>4B98F259-77FE-4FC0-9296-140C9C066977</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Danesh</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/95F764B3-B980-4210-87D7-B24034F7540A"><gtr:id>95F764B3-B980-4210-87D7-B24034F7540A</gtr:id><gtr:firstName>Leena</gtr:firstName><gtr:surname>Peltonen</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/2AEFFE89-5F99-4D21-85C4-BF0D68238CE6"><gtr:id>2AEFFE89-5F99-4D21-85C4-BF0D68238CE6</gtr:id><gtr:firstName>Danish</gtr:firstName><gtr:surname>Saleheen</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0801566"><gtr:id>C01045E1-FA74-4B07-AED7-A47AC2BC0EC7</gtr:id><gtr:title>Genetic analyses to test the causal relevance of lipoprotein(a) levels to coronary disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801566</gtr:grantReference><gtr:abstractText>Heart attacks and strokes account for almost 1 in every 2 adult deaths worldwide, and coronary heart disease is the single leading killer in the UK. Major established causes of heart disease include diabetes, smoking, and higher levels of blood pressure and blood cholesterol. If further blood components can be shown to be additional important causes of heart disease, then this should lead to improvements in the prediction and prevention of the disease, exemplified by measurement and modification of blood cholesterol levels. 

Lipoprotein(a) (?Lp[a]?) is a very large protein wrapped around a ?bad cholesterol? molecule that may promote narrowing of arteries that precedes heart attacks. Over the past few decades, there have been many reports of correlations between blood levels of Lp(a) and subsequent risk of heart disease. It is not clear from such studies, however, whether Lp(a) concentration is mainly a cause or a consequence of heart disease. 

We have proposed a series of large genetic studies in order to help judge whether Lp(a) is likely to have a cause-and-effect relation relationship with heart disease. Because genetic factors that influence blood Lp(a) level are fixed at conception, such genetic information may be used in sufficiently large studies to help distinguish causality from mere correlation. 

In particular, we will characterise the genetic, biochemical and other correlates of blood Lp(a) levels in 20,000 European and South Asian people, in whom comprehensive genetic profiling has already been completed. We will use this information to pinpoint the key genetic determinants of blood Lp(a) levels in the same 20,000 people. These key genetic factors will then be assessed in the stored genetic samples of about 30,000 patients with heart disease and of about 70,000 healthy people. Statistical tests for consistency will be done across these databases to help determine whether genetic information supports a causal role for Lp(a) in heart disease. 

The findings of this work should provide important scientific insights, helping to prioritise efforts to develop disease prevention strategies against Lp(a) and to interpret findings from ongoing large clinical trials of niacin (a drug that moderately lowers blood levels of Lp[a] and several other blood fats).</gtr:abstractText><gtr:technicalSummary>Lipoprotein(a) (Lp[a]), a very large glycoprotein wrapped around an LDL-like particle, has been implicated in coronary heart disease (CHD), but causality remains uncertain. The current proposal involves a series of genetic studies to help test causality by: 

(1) assay of Lp(a) levels in 20,000 healthy European and South Asian people in whom genome wide association scans, biochemical profiling and other detailed phenotyping have already been done, enabling powerful and cost-effective characterisation of Lp(a) correlates and distributions; 

(2) combination of genome wide and gene?centric approaches in the same 20,000 participants to identify key genetic variants at the LPA gene (the major determinant of Lp[a] levels) that influence circulating levels of Lp(a); 

(3) genotyping a relatively small number of key SNPs that show reproducible statistical associations with Lp(a) levels in a total of about 29,000 CHD cases and 69,000 controls in an existing consortium; and 

(4) integration of the gene-Lp(a) and gene-CHD data generated in the studies above with data on Lp(a)-CHD associations, such as from the separately funded Emerging Risk Factors Collaboration of 120,000 participants (8500 incident CHD cases) with Lp(a) levels. 

Assessment for numerical consistency of these varying sources of data (ie, a ?Mendelian randomisation analysis?) will enable judgement of the likelihood and magnitude of any causal association of Lp(a) concentration with CHD. Findings from the proposed studies should have considerable translational implications for existing drugs (eg, niacin non-specifically lowers Lp[a] levels by about 20%), for the development of new preventative strategies, and for novel mechanistic insights.</gtr:technicalSummary><gtr:fund><gtr:end>2012-04-20</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-04-21</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>561938</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Genomics and Global Health</gtr:department><gtr:description>African Partnership for Chronic Disease Research</gtr:description><gtr:id>BAE314BE-A21E-4E54-B2F8-BD7BB52585B3</gtr:id><gtr:impact>Two successful grant application have resulted so far from this partnership:

Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa
2013-2018 &amp;pound;2,550,000

MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA)
2013-2018 &amp;pound;885,314
 
The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.</gtr:impact><gtr:partnerContribution>The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions.
African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.</gtr:partnerContribution><gtr:piContribution>1. Set-up and coordination of the partnership.
2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health.
3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>Gambia, Republic of the</gtr:country><gtr:department>MRC Unit, The Gambia</gtr:department><gtr:description>African Partnership for Chronic Disease Research</gtr:description><gtr:id>012DB5F7-5992-4905-B9AB-6641AACF900E</gtr:id><gtr:impact>Two successful grant application have resulted so far from this partnership:

Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa
2013-2018 &amp;pound;2,550,000

MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA)
2013-2018 &amp;pound;885,314
 
The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.</gtr:impact><gtr:partnerContribution>The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions.
African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.</gtr:partnerContribution><gtr:piContribution>1. Set-up and coordination of the partnership.
2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health.
3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institutes of Health (NIH)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>National Human Genome Research Institute (NHGRI)</gtr:department><gtr:description>African Partnership for Chronic Disease Research</gtr:description><gtr:id>25216C7A-97DE-4665-B01F-337971E6E2D3</gtr:id><gtr:impact>Two successful grant application have resulted so far from this partnership:

Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa
2013-2018 &amp;pound;2,550,000

MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA)
2013-2018 &amp;pound;885,314
 
The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.</gtr:impact><gtr:partnerContribution>The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions.
African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.</gtr:partnerContribution><gtr:piContribution>1. Set-up and coordination of the partnership.
2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health.
3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>Uganda, Republic of</gtr:country><gtr:department>Medical Research Council (MRC), MRC/UVRI Unit, Uganda</gtr:department><gtr:description>African Partnership for Chronic Disease Research</gtr:description><gtr:id>AF2EB001-09F5-424F-8BC0-93C81D59007D</gtr:id><gtr:impact>Two successful grant application have resulted so far from this partnership:

Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa
2013-2018 &amp;pound;2,550,000

MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA)
2013-2018 &amp;pound;885,314
 
The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.</gtr:impact><gtr:partnerContribution>The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions.
African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.</gtr:partnerContribution><gtr:piContribution>1. Set-up and coordination of the partnership.
2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health.
3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Conakry</gtr:collaboratingOrganisation><gtr:country>Guinea, Republic of</gtr:country><gtr:description>African Partnership for Chronic Disease Research</gtr:description><gtr:id>CFB16B1D-B0EE-4F9D-A525-85E8C8A2AFE6</gtr:id><gtr:impact>Two successful grant application have resulted so far from this partnership:

Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa
2013-2018 &amp;pound;2,550,000

MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA)
2013-2018 &amp;pound;885,314
 
The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.</gtr:impact><gtr:partnerContribution>The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions.
African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.</gtr:partnerContribution><gtr:piContribution>1. Set-up and coordination of the partnership.
2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health.
3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MRC/UVRI Uganda Research Unit on AIDS</gtr:collaboratingOrganisation><gtr:country>Uganda, Republic of</gtr:country><gtr:description>Lp(a) levels in a population from sub-Saharan Africa</gtr:description><gtr:id>B86F958C-A432-4256-8E1B-05B8123D7A60</gtr:id><gtr:impact>We now have data on more than 8,000 study participants from Uganda, which will be compared with data from 20,000 Europeans and 20,000 South Asians. This is a multi-disciplinary collaboration involving clinicians, epidemiologists and geneticists.</gtr:impact><gtr:partnerContribution>One of our primary research mandates for the current grant was to the characterise the correlates of Lp(a) levels in different populations using standardised measurements (Objective 1). We originally focused on populations of European and South Asian descent. This collaboration allowed us to extend these studies to populations from sub-Saharan Africa. Importantly, it has been suggested that elevated levels of lipoprotein(a) [Lp(a)] are a risk marker for coronary heart disease in European populations, but not among African Americans. This is despite the observation that African American populatons have both higher Lp(a) levels and higher absolute cardiovascular event rates. There is a paucity of such data in populations from Africa, where the varying genetic background may alter the association between the cognate gene and Lp(a) levels. We aim to compare data across European, Souh Asian and African populations.</gtr:partnerContribution><gtr:piContribution>Together with MRC/UVRI, and with independent MRC grant funding we have devised and conducted a large scale study in Uganda--assessing the distribution of cardiometabolic risk factors. Within context of the current MRC grant funding, we aim to examine the distribution of Lp(a) and other risk factors for heart disease in this population.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cape Town</gtr:collaboratingOrganisation><gtr:country>South Africa, Republic of</gtr:country><gtr:description>African Partnership for Chronic Disease Research</gtr:description><gtr:id>16E2204C-17F5-4662-A990-18526068C3B7</gtr:id><gtr:impact>Two successful grant application have resulted so far from this partnership:

Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa
2013-2018 &amp;pound;2,550,000

MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA)
2013-2018 &amp;pound;885,314
 
The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.</gtr:impact><gtr:partnerContribution>The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions.
African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.</gtr:partnerContribution><gtr:piContribution>1. Set-up and coordination of the partnership.
2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health.
3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Wellcome Trust Sanger Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>African Partnership for Chronic Disease Research</gtr:description><gtr:id>04DD6494-9863-42AB-8984-8BEA07DB4642</gtr:id><gtr:impact>Two successful grant application have resulted so far from this partnership:

Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa
2013-2018 &amp;pound;2,550,000

MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA)
2013-2018 &amp;pound;885,314
 
The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.</gtr:impact><gtr:partnerContribution>The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions.
African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.</gtr:partnerContribution><gtr:piContribution>1. Set-up and coordination of the partnership.
2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health.
3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Ibadan</gtr:collaboratingOrganisation><gtr:country>Nigeria, Federal Republic of</gtr:country><gtr:description>African Partnership for Chronic Disease Research</gtr:description><gtr:id>7DECFECD-CF89-4926-8636-02C6857B2C7C</gtr:id><gtr:impact>Two successful grant application have resulted so far from this partnership:

Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa
2013-2018 &amp;pound;2,550,000

MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA)
2013-2018 &amp;pound;885,314
 
The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.</gtr:impact><gtr:partnerContribution>The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions.
African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.</gtr:partnerContribution><gtr:piContribution>1. Set-up and coordination of the partnership.
2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health.
3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nigeria</gtr:collaboratingOrganisation><gtr:country>Nigeria, Federal Republic of</gtr:country><gtr:department>University of Nigeria Teaching Hospital (UNTH) Ituku/Ozalla Enugu</gtr:department><gtr:description>African Partnership for Chronic Disease Research</gtr:description><gtr:id>303F3999-0FC0-4D87-BE7A-F4CBB2B0751F</gtr:id><gtr:impact>Two successful grant application have resulted so far from this partnership:

Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa
2013-2018 &amp;pound;2,550,000

MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA)
2013-2018 &amp;pound;885,314
 
The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.</gtr:impact><gtr:partnerContribution>The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions.
African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.</gtr:partnerContribution><gtr:piContribution>1. Set-up and coordination of the partnership.
2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health.
3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Ghana</gtr:collaboratingOrganisation><gtr:country>Ghana, Republic of</gtr:country><gtr:department>School of Medicine</gtr:department><gtr:description>African Partnership for Chronic Disease Research</gtr:description><gtr:id>59EF3326-6961-4E11-B281-79E471BDACA0</gtr:id><gtr:impact>Two successful grant application have resulted so far from this partnership:

Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa
2013-2018 &amp;pound;2,550,000

MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA)
2013-2018 &amp;pound;885,314
 
The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.</gtr:impact><gtr:partnerContribution>The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions.
African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.</gtr:partnerContribution><gtr:piContribution>1. Set-up and coordination of the partnership.
2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health.
3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Yaound?</gtr:collaboratingOrganisation><gtr:country>Cameroon, Republic of</gtr:country><gtr:description>African Partnership for Chronic Disease Research</gtr:description><gtr:id>F2BB8762-FEC2-4661-AB17-B55DD2A394DC</gtr:id><gtr:impact>Two successful grant application have resulted so far from this partnership:

Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa
2013-2018 &amp;pound;2,550,000

MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA)
2013-2018 &amp;pound;885,314
 
The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.</gtr:impact><gtr:partnerContribution>The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions.
African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.</gtr:partnerContribution><gtr:piContribution>1. Set-up and coordination of the partnership.
2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health.
3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Moi University</gtr:collaboratingOrganisation><gtr:country>Kenya, Republic of</gtr:country><gtr:department>School of Medicine</gtr:department><gtr:description>African Partnership for Chronic Disease Research</gtr:description><gtr:id>1C33B402-7559-4B85-AFC4-91CFFF9F8C03</gtr:id><gtr:impact>Two successful grant application have resulted so far from this partnership:

Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa
2013-2018 &amp;pound;2,550,000

MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA)
2013-2018 &amp;pound;885,314
 
The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.</gtr:impact><gtr:partnerContribution>The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions.
African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.</gtr:partnerContribution><gtr:piContribution>1. Set-up and coordination of the partnership.
2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health.
3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Medical Research, Tanzania</gtr:collaboratingOrganisation><gtr:country>Tanzania, United Republic of</gtr:country><gtr:department>Mwanza Intervention Trials Unit (MITU)</gtr:department><gtr:description>African Partnership for Chronic Disease Research</gtr:description><gtr:id>57752E98-E6CE-45FD-ABC5-588F2B7E3E3D</gtr:id><gtr:impact>Two successful grant application have resulted so far from this partnership:

Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa
2013-2018 &amp;pound;2,550,000

MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA)
2013-2018 &amp;pound;885,314
 
The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.</gtr:impact><gtr:partnerContribution>The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions.
African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.</gtr:partnerContribution><gtr:piContribution>1. Set-up and coordination of the partnership.
2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health.
3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Addenbrooke's Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Epidemiology Unit</gtr:department><gtr:description>African Partnership for Chronic Disease Research</gtr:description><gtr:id>DC4C26E7-F972-4950-9060-FB9B17C1B92A</gtr:id><gtr:impact>Two successful grant application have resulted so far from this partnership:

Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa
2013-2018 &amp;pound;2,550,000

MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA)
2013-2018 &amp;pound;885,314
 
The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.</gtr:impact><gtr:partnerContribution>The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions.
African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.</gtr:partnerContribution><gtr:piContribution>1. Set-up and coordination of the partnership.
2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health.
3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of KwaZulu-Natal</gtr:collaboratingOrganisation><gtr:country>South Africa, Republic of</gtr:country><gtr:description>African Partnership for Chronic Disease Research</gtr:description><gtr:id>70A2DA82-AF0F-430E-9ECF-F84AD15E16D1</gtr:id><gtr:impact>Two successful grant application have resulted so far from this partnership:

Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa
2013-2018 &amp;pound;2,550,000

MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA)
2013-2018 &amp;pound;885,314
 
The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.</gtr:impact><gtr:partnerContribution>The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions.
African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.</gtr:partnerContribution><gtr:piContribution>1. Set-up and coordination of the partnership.
2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health.
3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>London School of Hygiene and Tropical Medicine (LSHTM)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>African Partnership for Chronic Disease Research</gtr:description><gtr:id>C4ECF0C2-98DA-47CC-A6B1-C4CDB1F63B1A</gtr:id><gtr:impact>Two successful grant application have resulted so far from this partnership:

Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa
2013-2018 &amp;pound;2,550,000

MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA)
2013-2018 &amp;pound;885,314
 
The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.</gtr:impact><gtr:partnerContribution>The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions.
African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.</gtr:partnerContribution><gtr:piContribution>1. Set-up and coordination of the partnership.
2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health.
3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>African Partnership for Chronic Disease Research</gtr:description><gtr:id>2067E1C3-9E4C-44F9-801D-09B7F15F4F8E</gtr:id><gtr:impact>Two successful grant application have resulted so far from this partnership:

Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa
2013-2018 &amp;pound;2,550,000

MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA)
2013-2018 &amp;pound;885,314
 
The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.</gtr:impact><gtr:partnerContribution>The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions.
African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.</gtr:partnerContribution><gtr:piContribution>1. Set-up and coordination of the partnership.
2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health.
3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Human Genome Center; Howard University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>African Partnership for Chronic Disease Research</gtr:description><gtr:id>6C4789AF-253B-4AD2-AF7C-496C165922F0</gtr:id><gtr:impact>Two successful grant application have resulted so far from this partnership:

Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa
2013-2018 &amp;pound;2,550,000

MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA)
2013-2018 &amp;pound;885,314
 
The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.</gtr:impact><gtr:partnerContribution>The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions.
African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.</gtr:partnerContribution><gtr:piContribution>1. Set-up and coordination of the partnership.
2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health.
3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of the Witwatersrand</gtr:collaboratingOrganisation><gtr:country>South Africa, Republic of</gtr:country><gtr:description>African Partnership for Chronic Disease Research</gtr:description><gtr:id>FF279A67-68EB-4548-A5AB-BEBD2C611880</gtr:id><gtr:impact>Two successful grant application have resulted so far from this partnership:

Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa
2013-2018 &amp;pound;2,550,000

MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA)
2013-2018 &amp;pound;885,314
 
The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.</gtr:impact><gtr:partnerContribution>The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions.
African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.</gtr:partnerContribution><gtr:piContribution>1. Set-up and coordination of the partnership.
2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health.
3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Wellcome Trust Centre for Human Genetics</gtr:department><gtr:description>African Partnership for Chronic Disease Research</gtr:description><gtr:id>103F6254-9B79-45F9-AEFD-EADBC718AC9F</gtr:id><gtr:impact>Two successful grant application have resulted so far from this partnership:

Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa
2013-2018 &amp;pound;2,550,000

MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA)
2013-2018 &amp;pound;885,314
 
The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.</gtr:impact><gtr:partnerContribution>The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions.
African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.</gtr:partnerContribution><gtr:piContribution>1. Set-up and coordination of the partnership.
2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health.
3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of the Gambia</gtr:collaboratingOrganisation><gtr:country>Gambia, Republic of the</gtr:country><gtr:description>African Partnership for Chronic Disease Research</gtr:description><gtr:id>F7FFA04C-EE9B-41F5-9B46-88AC6ECA55BE</gtr:id><gtr:impact>Two successful grant application have resulted so far from this partnership:

Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa
2013-2018 &amp;pound;2,550,000

MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA)
2013-2018 &amp;pound;885,314
 
The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.</gtr:impact><gtr:partnerContribution>The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions.
African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.</gtr:partnerContribution><gtr:piContribution>1. Set-up and coordination of the partnership.
2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health.
3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Wellcome Trust Ltd</gtr:collaboratingOrganisation><gtr:country>Malawi, Republic of</gtr:country><gtr:department>Malawi-Liverpool Wellcome Trust Clinical Research Programme</gtr:department><gtr:description>African Partnership for Chronic Disease Research</gtr:description><gtr:id>4591F0B3-9C55-4D38-9EB5-B9CEBFAB2B02</gtr:id><gtr:impact>Two successful grant application have resulted so far from this partnership:

Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa
2013-2018 &amp;pound;2,550,000

MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA)
2013-2018 &amp;pound;885,314
 
The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.</gtr:impact><gtr:partnerContribution>The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions.
African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.</gtr:partnerContribution><gtr:piContribution>1. Set-up and coordination of the partnership.
2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health.
3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Makerere University College of Health Sciences</gtr:collaboratingOrganisation><gtr:country>Uganda, Republic of</gtr:country><gtr:description>African Partnership for Chronic Disease Research</gtr:description><gtr:id>7E0A4FBA-1718-4EF2-8819-C7C98C053EA8</gtr:id><gtr:impact>Two successful grant application have resulted so far from this partnership:

Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa
2013-2018 &amp;pound;2,550,000

MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA)
2013-2018 &amp;pound;885,314
 
The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.</gtr:impact><gtr:partnerContribution>The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions.
African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.</gtr:partnerContribution><gtr:piContribution>1. Set-up and coordination of the partnership.
2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health.
3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2550000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust H3Africa</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:fundingRef>060743</gtr:fundingRef><gtr:id>80575C3F-0DA7-4A05-842C-960D95F1859D</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>As part of an analysis to identify high frequency genetic variants at the population level, we have sequenced whole genomes at low and high coverage from sub-Saharan Africa and South Asia. These data will be publicly available through managed databases.</gtr:description><gtr:id>81D3BFD6-B66F-4E1B-AE83-863F8BE6834F</gtr:id><gtr:impact>The sequencing data will be publicly available to the scientific community.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Sequencing data on human genomes</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/04AC7292-50BA-4D9A-BB79-7AA757F7D5FA"><gtr:id>04AC7292-50BA-4D9A-BB79-7AA757F7D5FA</gtr:id><gtr:title>Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort.</gtr:title><gtr:parentPublicationTitle>Circulation. Cardiovascular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fc3c0387fcc89b181798aa33ec6a4313"><gtr:id>fc3c0387fcc89b181798aa33ec6a4313</gtr:id><gtr:otherNames>Arsenault BJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1942-3268</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/639A9578-3F03-4AB5-A1C1-F451B9235FBA"><gtr:id>639A9578-3F03-4AB5-A1C1-F451B9235FBA</gtr:id><gtr:title>Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/35ac4d52038241a41c9817f6d48f885d"><gtr:id>35ac4d52038241a41c9817f6d48f885d</gtr:id><gtr:otherNames>C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DAEEE81F-377F-49F7-9B12-011C02ECD556"><gtr:id>DAEEE81F-377F-49F7-9B12-011C02ECD556</gtr:id><gtr:title>Linear mixed model for heritability estimation that explicitly addresses environmental variation.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/67ab9ab259e6b8bd70c9cc9febc63c01"><gtr:id>67ab9ab259e6b8bd70c9cc9febc63c01</gtr:id><gtr:otherNames>Heckerman D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B5957DA9-E377-4799-B127-9A7C606A8AE2"><gtr:id>B5957DA9-E377-4799-B127-9A7C606A8AE2</gtr:id><gtr:title>Cardiometabolic risk in a rural Ugandan population.</gtr:title><gtr:parentPublicationTitle>Diabetes care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f47eb64547138514afe3839c3e85b281"><gtr:id>f47eb64547138514afe3839c3e85b281</gtr:id><gtr:otherNames>Murphy GA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0149-5992</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6A7A56F0-35CF-4B91-8DA9-6CB199504042"><gtr:id>6A7A56F0-35CF-4B91-8DA9-6CB199504042</gtr:id><gtr:title>Meta analysis of candidate gene variants outside the LPA locus with Lp(a) plasma levels in 14,500 participants of six White European cohorts.</gtr:title><gtr:parentPublicationTitle>Atherosclerosis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f77d593c25ed325f895f23e538023a02"><gtr:id>f77d593c25ed325f895f23e538023a02</gtr:id><gtr:otherNames>Zabaneh D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9150</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/95FDDACC-1AF6-4B39-95B3-23E51FD7035D"><gtr:id>95FDDACC-1AF6-4B39-95B3-23E51FD7035D</gtr:id><gtr:title>Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study.</gtr:title><gtr:parentPublicationTitle>Journal of the American College of Cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/856bb22275735c6a7534e465be5a3e8c"><gtr:id>856bb22275735c6a7534e465be5a3e8c</gtr:id><gtr:otherNames>Holmes MV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0735-1097</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A5A360CB-3022-4832-924A-C5A02DCD45F2"><gtr:id>A5A360CB-3022-4832-924A-C5A02DCD45F2</gtr:id><gtr:title>Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4cf513374aefc525998bd45102347c56"><gtr:id>4cf513374aefc525998bd45102347c56</gtr:id><gtr:otherNames>Sofat R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BE321F24-2487-4D89-A1E3-B76A51AEE092"><gtr:id>BE321F24-2487-4D89-A1E3-B76A51AEE092</gtr:id><gtr:title>Both paraoxonase-1 genotype and activity do not predict the risk of future coronary artery disease; the EPIC-Norfolk Prospective Population Study.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f70c77f3392946055512af6533972e93"><gtr:id>f70c77f3392946055512af6533972e93</gtr:id><gtr:otherNames>Birjmohun RS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/194204EF-C626-40DD-96D5-357BDA011920"><gtr:id>194204EF-C626-40DD-96D5-357BDA011920</gtr:id><gtr:title>Biological, clinical and population relevance of 95 loci for blood lipids.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bd8c9fb6985db97fd510d0a591e68e20"><gtr:id>bd8c9fb6985db97fd510d0a591e68e20</gtr:id><gtr:otherNames>Teslovich TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FC8D2C08-7915-4A35-8514-C7A41AFC0444"><gtr:id>FC8D2C08-7915-4A35-8514-C7A41AFC0444</gtr:id><gtr:title>The association between circulating lipoprotein(a) and type 2 diabetes: is it causal?</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0737230de95b4af7036a0056f2039d97"><gtr:id>0737230de95b4af7036a0056f2039d97</gtr:id><gtr:otherNames>Ye Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C7530437-6BF9-4EE2-AD2C-B331B53C4EAD"><gtr:id>C7530437-6BF9-4EE2-AD2C-B331B53C4EAD</gtr:id><gtr:title>Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c28a8e3c01a5869f6ea0a4fb7405366d"><gtr:id>c28a8e3c01a5869f6ea0a4fb7405366d</gtr:id><gtr:otherNames>Lp-PLA(2) Studies Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C9C106DC-3BE5-4C30-A62B-D1E5DD6C7EA0"><gtr:id>C9C106DC-3BE5-4C30-A62B-D1E5DD6C7EA0</gtr:id><gtr:title>Discovery and refinement of loci associated with lipid levels.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e03e206b167fce79060e932a8719994b"><gtr:id>e03e206b167fce79060e932a8719994b</gtr:id><gtr:otherNames>Global Lipids Genetics Consortium</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/931C9D3F-A3D6-46CD-BCE5-77C4C862DF9D"><gtr:id>931C9D3F-A3D6-46CD-BCE5-77C4C862DF9D</gtr:id><gtr:title>Mendelian randomization studies do not support a role for raised circulating triglyceride levels influencing type 2 diabetes, glucose levels, or insulin resistance.</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b4b7bc19305dd6af580828a208894462"><gtr:id>b4b7bc19305dd6af580828a208894462</gtr:id><gtr:otherNames>De Silva NM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1A4762AE-4C6C-400E-9303-9E828FEA9929"><gtr:id>1A4762AE-4C6C-400E-9303-9E828FEA9929</gtr:id><gtr:title>Urbanicity and lifestyle risk factors for cardiometabolic diseases in rural Uganda: a cross-sectional study.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9990da26a2d0066df4d249152c565cf1"><gtr:id>9990da26a2d0066df4d249152c565cf1</gtr:id><gtr:otherNames>Riha J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BE880C91-243F-47B1-992F-DA4E265DB6D7"><gtr:id>BE880C91-243F-47B1-992F-DA4E265DB6D7</gtr:id><gtr:title>Genetic determinants of lipid homeostasis.</gtr:title><gtr:parentPublicationTitle>Best practice &amp; research. Clinical endocrinology &amp; metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/94415bc8f447f836df457d21b3fee856"><gtr:id>94415bc8f447f836df457d21b3fee856</gtr:id><gtr:otherNames>Young EH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1521-690X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6A8F246E-B64E-4355-8DAA-3297B469655A"><gtr:id>6A8F246E-B64E-4355-8DAA-3297B469655A</gtr:id><gtr:title>Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4832a811237e349a300010863ec47d33"><gtr:id>4832a811237e349a300010863ec47d33</gtr:id><gtr:otherNames>Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B7E62A5F-05E6-49B4-B936-4737FCB25CD7"><gtr:id>B7E62A5F-05E6-49B4-B936-4737FCB25CD7</gtr:id><gtr:title>Prevalence of dyslipidaemia and associated risk factors in a rural population in South-Western Uganda: a community based survey.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1b1d4a56327da023eec14c05d69572b2"><gtr:id>1b1d4a56327da023eec14c05d69572b2</gtr:id><gtr:otherNames>Asiki G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9F87BF44-B123-4D2F-BD45-16E830F24A70"><gtr:id>9F87BF44-B123-4D2F-BD45-16E830F24A70</gtr:id><gtr:title>The African Genome Variation Project shapes medical genetics in Africa.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/028c877b2dbe31d6e55c00dfe30822ee"><gtr:id>028c877b2dbe31d6e55c00dfe30822ee</gtr:id><gtr:otherNames>Gurdasani D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/41179C26-F981-4CC0-8E5B-EDD5492BFC48"><gtr:id>41179C26-F981-4CC0-8E5B-EDD5492BFC48</gtr:id><gtr:title>Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study.</gtr:title><gtr:parentPublicationTitle>Journal of lipid research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a12acc979b91fc30a4e78b0cb77a961c"><gtr:id>a12acc979b91fc30a4e78b0cb77a961c</gtr:id><gtr:otherNames>Verbeek R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-2275</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9CC33695-DA14-42C0-86CA-ACF98EC42BF7"><gtr:id>9CC33695-DA14-42C0-86CA-ACF98EC42BF7</gtr:id><gtr:title>Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study.</gtr:title><gtr:parentPublicationTitle>Arteriosclerosis, thrombosis, and vascular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/028c877b2dbe31d6e55c00dfe30822ee"><gtr:id>028c877b2dbe31d6e55c00dfe30822ee</gtr:id><gtr:otherNames>Gurdasani D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1079-5642</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DFCE0CAD-7D6A-4C88-8982-C18488E6096F"><gtr:id>DFCE0CAD-7D6A-4C88-8982-C18488E6096F</gtr:id><gtr:title>Genetic variants influencing circulating lipid levels and risk of coronary artery disease.</gtr:title><gtr:parentPublicationTitle>Arteriosclerosis, thrombosis, and vascular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4011c795ea4562c359cc7ce8fb154ee4"><gtr:id>4011c795ea4562c359cc7ce8fb154ee4</gtr:id><gtr:otherNames>Waterworth DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1079-5642</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0A4ADF6B-949E-4BD9-8CBF-F0CF63598E30"><gtr:id>0A4ADF6B-949E-4BD9-8CBF-F0CF63598E30</gtr:id><gtr:title>Large-scale association analysis identifies new risk loci for coronary artery disease.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f10abe080ea072f120714f3fbee29092"><gtr:id>f10abe080ea072f120714f3fbee29092</gtr:id><gtr:otherNames>CARDIoGRAMplusC4D Consortium</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/425236C2-FAEB-43F6-8CEC-E3FE6EDE2562"><gtr:id>425236C2-FAEB-43F6-8CEC-E3FE6EDE2562</gtr:id><gtr:title>Inflammatory biomarkers and the prediction of coronary events among people at intermediate risk: the EPIC-Norfolk prospective population study.</gtr:title><gtr:parentPublicationTitle>Heart (British Cardiac Society)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ed22cfc512262df2052271c49b8629bb"><gtr:id>ed22cfc512262df2052271c49b8629bb</gtr:id><gtr:otherNames>Rana JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1355-6037</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DEA96111-03FB-44E0-B0C9-BCC9E76DACCF"><gtr:id>DEA96111-03FB-44E0-B0C9-BCC9E76DACCF</gtr:id><gtr:title>Family history of premature coronary heart disease and risk prediction in the EPIC-Norfolk prospective population study.</gtr:title><gtr:parentPublicationTitle>Heart (British Cardiac Society)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/edec38ae83d4017f0984375e6bd63947"><gtr:id>edec38ae83d4017f0984375e6bd63947</gtr:id><gtr:otherNames>Sivapalaratnam S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1355-6037</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BF04247E-BC88-4DD7-8C35-419F3C2CBC84"><gtr:id>BF04247E-BC88-4DD7-8C35-419F3C2CBC84</gtr:id><gtr:title>Chemokine ligand 2 genetic variants, serum monocyte chemoattractant protein-1 levels, and the risk of coronary artery disease.</gtr:title><gtr:parentPublicationTitle>Arteriosclerosis, thrombosis, and vascular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/550e3e6020d424c05eff1e86be5bfc0f"><gtr:id>550e3e6020d424c05eff1e86be5bfc0f</gtr:id><gtr:otherNames>van Wijk DF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1079-5642</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/366FA254-D2CF-4DD8-A02E-EF17760E1C06"><gtr:id>366FA254-D2CF-4DD8-A02E-EF17760E1C06</gtr:id><gtr:title>Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: The EPIC-Norfolk prospective population study.</gtr:title><gtr:parentPublicationTitle>Atherosclerosis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/00493b523dc99eb1b7185d26873d90f6"><gtr:id>00493b523dc99eb1b7185d26873d90f6</gtr:id><gtr:otherNames>Perrot N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0021-9150</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2BEED353-94DF-4B07-85B0-4F1E8BC27FA8"><gtr:id>2BEED353-94DF-4B07-85B0-4F1E8BC27FA8</gtr:id><gtr:title>Common variants associated with plasma triglycerides and risk for coronary artery disease.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6daa1058761b1f7343dc0121c98d2a04"><gtr:id>6daa1058761b1f7343dc0121c98d2a04</gtr:id><gtr:otherNames>Do R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/41BB2C5D-38E9-4643-86F8-9E5E3CF98773"><gtr:id>41BB2C5D-38E9-4643-86F8-9E5E3CF98773</gtr:id><gtr:title>PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cf19195b6da69f15f5912aea3dcb019e"><gtr:id>cf19195b6da69f15f5912aea3dcb019e</gtr:id><gtr:otherNames>Casas JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BAB330EB-9713-424B-B78D-5FEDCF0BF75B"><gtr:id>BAB330EB-9713-424B-B78D-5FEDCF0BF75B</gtr:id><gtr:title>Apolipoprotein E genotype, cardiovascular biomarkers and risk of stroke: systematic review and meta-analysis of 14,015 stroke cases and pooled analysis of primary biomarker data from up to 60,883 individuals.</gtr:title><gtr:parentPublicationTitle>International journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/25361a2b551ea51ecf4de98eef4ae81f"><gtr:id>25361a2b551ea51ecf4de98eef4ae81f</gtr:id><gtr:otherNames>Khan TA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0300-5771</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9FF90A41-0334-4018-9A54-82B9E86C7641"><gtr:id>9FF90A41-0334-4018-9A54-82B9E86C7641</gtr:id><gtr:title>Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bbca6510bdfa10166be62b369cdd718f"><gtr:id>bbca6510bdfa10166be62b369cdd718f</gtr:id><gtr:otherNames>Zanoni P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F218BB79-4C82-4B1C-8B46-84C49AB4EE1E"><gtr:id>F218BB79-4C82-4B1C-8B46-84C49AB4EE1E</gtr:id><gtr:title>Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b198b0e7d7d33d1cbdbe32a0ef0394be"><gtr:id>b198b0e7d7d33d1cbdbe32a0ef0394be</gtr:id><gtr:otherNames>Schunkert H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/80D28794-B4A1-42B1-8A57-1EA7CC811953"><gtr:id>80D28794-B4A1-42B1-8A57-1EA7CC811953</gtr:id><gtr:title>A genome-wide screen for interactions reveals a new locus on 4p15 modifying the effect of waist-to-hip ratio on total cholesterol.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/139f6ac5c53e4503e84d5a5d407ea224"><gtr:id>139f6ac5c53e4503e84d5a5d407ea224</gtr:id><gtr:otherNames>Surakka I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A55261A6-6E77-4E61-A7E9-8562CBB709FF"><gtr:id>A55261A6-6E77-4E61-A7E9-8562CBB709FF</gtr:id><gtr:title>Genomic risk prediction.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f7b2894b010199947c9b4af16ad235bb"><gtr:id>f7b2894b010199947c9b4af16ad235bb</gtr:id><gtr:otherNames>Sandhu M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EDA4630A-A3BF-4595-B58B-664E503BCEBF"><gtr:id>EDA4630A-A3BF-4595-B58B-664E503BCEBF</gtr:id><gtr:title>Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events.</gtr:title><gtr:parentPublicationTitle>Journal of the American College of Cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/016bab0061bdd8558cef5b9bf14968ed"><gtr:id>016bab0061bdd8558cef5b9bf14968ed</gtr:id><gtr:otherNames>Tsimikas S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0735-1097</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BF2FD7E6-23B5-457B-9F0A-F744E4E2442A"><gtr:id>BF2FD7E6-23B5-457B-9F0A-F744E4E2442A</gtr:id><gtr:title>Genetic variation at the phospholipid transfer protein locus affects its activity and high-density lipoprotein size and is a novel marker of cardiovascular disease susceptibility.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ca028c18febcbe6ae9a9ba9c7db8fa3e"><gtr:id>ca028c18febcbe6ae9a9ba9c7db8fa3e</gtr:id><gtr:otherNames>Vergeer M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B724B3FC-D242-4E12-AB12-902246BA6F5B"><gtr:id>B724B3FC-D242-4E12-AB12-902246BA6F5B</gtr:id><gtr:title>Bayesian methods for meta-analysis of causal relationships estimated using genetic instrumental variables.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/056163b112d2b291ecc076d094a1b4e8"><gtr:id>056163b112d2b291ecc076d094a1b4e8</gtr:id><gtr:otherNames>Burgess S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801566</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>